Patients with LCNEC tumors that carry a wild-type RB1 gene or express the RB1 protein fare better with NSCLC-GEM/TAX treatment than with SCLC-PE chemotherapy. The gene discussed is RB1; the disease is large cell neuroendocrine carcinoma.